Table 2.
In-hospital examination and treatment
| Characteristics | Total (n=488) | Sinus rhythm (n=439) | NOAF (n=49) | p-value |
|---|---|---|---|---|
| Laboratory test | ||||
| Hemoglobin (g/L) | 139 (128–150) | 140 (128–151) | 134 (129–144) | 0.03 |
| WBC (×109/L) | 9.68 (7.82–12.06) | 9.50 (7.77–12.09) | 9.72 (6.94–12.26) | 0.70 |
| Platelet (×109/L) | 204 (169–243) | 203 (171–246) | 183 (157–238) | 0.14 |
| C-reactive protein (mg/L) | 4.09 (1.16–17.86) | 3.80 (1.16–17.50) | 6.80 (1.41–18.42) | 0.62 |
| Creatinine (μmol/L) | 80.8 (67.9–96.3) | 80.0 (67.8–95.9) | 81.0 (67.2–107.8) | 0.40 |
| eGFR (mL/min/1.73 m2) | 83.0±26.2 | 84.5±26.1 | 70.1±23.5 | <0.01 |
| Peak TnT (ng/mL) | 5.35 (1.79–10.00) | 5.11 (1.80–10.00) | 8.25 (1.29–10.00) | 0.25 |
| >100×ULNa (ng/mL) | 390 (79.9) | 354 (80.6) | 36 (73.5) | 0.24 |
| Peak NT-pro-BNP (pg/mL) | 1,762.5 (931.7–3,908.0) | 1,591.0 (839.7–3,259.0) | 6,126.0 (1,962.5–12,516.0) | <0.01 |
| >5×ULNb (pg/mL) | 312 (63.9) | 267 (60.8) | 45 (91.8) | <0.01 |
| Echocardiographyc | ||||
| LVEF (%) | 50.6±10.5 | 51.1±10.2 | 45.9±12.3 | 0.01 |
| Left atrial diameter (mm) | 39.0±4.7 | 38.9±4.6 | 40.6±5.3 | 0.02 |
| LVESD (mm) | 31.7±5.4 | 31.5±5.2 | 33.0±6.8 | 0.36 |
| LVEDD (mm) | 45.8±4.9 | 45.9±4.8 | 45.2±5.9 | 0.16 |
| Mitral regurgitation (%) | 0.35 | |||
| Mild | 220 (48.4) | 200 (48.9) | 20 (43.5) | |
| Moderate | 24 (5.3) | 20 (4.9) | 4 (8.7) | |
| Severe | 2 (0.4) | 1 (0.2) | 1 (2.2) | |
| Impaired mitral function (%)d | 26 (5.7) | 21 (5.1) | 5 (10.9) | 0.21 |
| Coronary angiography (%)e | ||||
| Ischemia-related artery | 0.97 | |||
| LAD | 248 (51.6) | 223 (51.4) | 25 (53.2) | |
| RCA | 191 (39.7) | 173 (39.9) | 18 (38.3) | |
| LCX | 42 (8.7) | 38 (8.8) | 4 (8.5) | |
| Multi-vessel disease | 203 (42.2) | 189 (43.5) | 14 (29.8) | 0.07 |
| In-hospital treatment (%) | ||||
| Antiplateletsf | 483 (99.0) | 435 (99.1) | 48 (98.0) | 0.41 |
| ACEI/ARB | 290 (59.7) | 260 (59.5) | 30 (61.2) | 0.82 |
| β-blockers | 356 (73.3) | 321 (73.5) | 35 (71.4) | 0.76 |
| CCB | 66 (13.6) | 60 (13.7) | 6 (12.2) | 0.77 |
| Statins | 476 (97.9) | 430 (98.4) | 46 (93.9) | 0.11 |
| Diuretic | 169 (34.8) | 132 (30.2) | 37 (75.5) | <0.01 |
| Inotropes | 159 (32.7) | 132 (30.2) | 27 (55.1) | <0.01 |
| PCI | 413 (84.6) | 375 (85.4) | 38 (77.6) | 0.15 |
| IABP | 25 (5.3) | 19 (4.3) | 7 (14.3) | 0.01 |
| Temporary pacemaker | 132 (27.0) | 119 (27.1) | 13 (26.5) | 0.93 |
Notes:
ULN=0.014 ng/mL,
ULN=234.4 pg/mL,
Data from 455 patients,
Includes moderate and severe mitral regurgitation,
Data from 481 patients,
Includes aspirin and P2Y12 inhibitors. Data presented as n (%), mean ± SD or median (IQR).
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; IABP, intra-aorta balloon pump; LAD, left anterior artery; LCX, left circumflex artery; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NOAF, new-onset atrial fibrillation; PCI, percutaneous coronary intervention; RCA, right coronary artery; TnT, troponin T; WBC, white blood cell; ULN, upper limit of normal.